洛铂联合吉西他滨治疗复发性卵巢癌36例临床分析

摘要

Objective To observe the efficacy and safety of lobaplatin combined gemcitabine for recurrent ovarian canc -er.Methods 70 patients with recurrent ovarian cancer were chosen and randomly divided into the experiment group (36 cases) and the control group (34 cases).The experiment group was given lobaplatin combined with gemcitabine while the control group was given paclitaxel combined with nedaplatin .Clinical effects and adverse reactions of the 2 groups were compared .Results Ef-fective rates of the experiment group and the control group were 61.11%and 44.12%,χ2 =4.25,P<0.05;disease control rates of the experiment group and the control group were 88.89%and 82.36%,χ2 =4.01,P<0.05.QOL score of the 2 groups before treatment had no significant difference ,t=0.38,P>0.05;QOL score of the 2 groups after treatment had significant difference ,t=3.24,P<0.05.Toxic reaction rates of the control group and the experiment group were 77.78%and 79.41%,χ2 =0.98,P>0.05.Conclusion Lobaplatin combined with gemcitabine has accurate clinical effect for recurrent ovarian cancer ,it can effec-tively improve life quality of patients without increase toxic reactions ,and it is worthy of clinical application .%目的：探讨洛铂联合吉西他滨治疗复发性卵巢癌的疗效和安全性。方法入选2010年3月-2012年2月复发性卵巢癌患者70例，随机分为试验组36例，对照组34例。试验组给予洛铂联合吉西他滨治疗，对照组给予紫杉醇联合奈达铂治疗，对比研究2组患者的临床疗效，同时对治疗的不良反应发生情况进行对比研究。结果试验组有效率为61．11％，对照组有效率为44．12％，2组有效率差异有统计学意义，χ2＝4．25，P＜0．05；试验组疾病控制率为88．89％，对照组疾病控制率为82．35％，差异有统计学意义，χ2＝4．01，P＜0．05。2组患者治疗前QOL评分差异无显著性，t＝0．38，P＞0．05；治疗后差异有统计学意义，t＝3．24，P＜0．05。试验组患者不良反应发生率为77．78％，对照组为79．41％，差异无统计学意义（χ2＝0．98，P＞0．05）。结论洛铂联合吉西他滨治疗复发性卵巢癌疗效确切，能够有效改善患者的生存质量，同时不增加毒性反应发生，值得临床推广应用。